Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 maintenance niraparib vs placebo in platinum-sensitive ovarian cancer
2013-000685-11Phase 3Completed
- Sponsor
- TESARO, Inc.
- Start
- Aug 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in ovarian cancer comparing Niraparib maintenance with Placebo maintenance (2 arms). Primary endpoint: Progression-Free Survival. Started Aug 2013; status: completed.
02
Drugs
niraparib
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on 2013-000685-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-000685-11.